Select therapeutic use:

Breast cancer:

Indications for Vinblastine for injection:

Less frequently responsive: breast cancer, unresponsive to endocrine surgery and hormonal therapy.

Adult:

See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

Children:

Not recommended.

Contraindications:

Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

Warnings/Precautions:

For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

Pharmacologic Class:

Antimicrotubule agent.

Interactions:

May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

Adverse Reactions:

Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

How Supplied:

Pwd—10; Soln—1

Gynecologic cancers:

Indications for Vinblastine for injection:

Less frequently responsive: choriocarcinoma resistant to other chemotherapy.

Adult:

See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

Children:

Not recommended.

Contraindications:

Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

Warnings/Precautions:

For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

Pharmacologic Class:

Antimicrotubule agent.

Interactions:

May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

Adverse Reactions:

Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

How Supplied:

Pwd—10; Soln—1

Kaposi's sarcoma:

Indications for Vinblastine for injection:

Frequently responsive: palliative treatment of Kaposi's sarcoma.

Adult:

See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

Children:

Not recommended.

Contraindications:

Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

Warnings/Precautions:

For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

Pharmacologic Class:

Antimicrotubule agent.

Interactions:

May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

Adverse Reactions:

Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

How Supplied:

Pwd—10; Soln—1

Leukemias, lymphomas, and other hematologic cancers:

Indications for Vinblastine for injection:

Frequently responsive: palliative treatment of generalized Hodgkin's disease, lymphocytic lymphoma, histiocytic lymphoma, mycosis fungoides.

Adult:

See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

Children:

See literature. IV use only. Hodgkin's disease: initially 6mg/m2. Adjust dose according to hematologic tolerance.

Contraindications:

Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

Warnings/Precautions:

For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

Pharmacologic Class:

Antimicrotubule agent.

Interactions:

May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

Adverse Reactions:

Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

How Supplied:

Pwd—10; Soln—1

Prostate and other male cancers:

Indications for Vinblastine for injection:

Frequently responsive: palliative treatment of advanced carcinoma of the testis.

Adult:

See literature. Give by IV once weekly. 1st dose: 3.7mg/m2 as a single dose, continue to increase dose by increments (2nd dose: 5.5mg/m2, 3rd dose: 7.4mg/m2, 4th dose: 9.25mg/m2, 5th dose: 11.1mg/m2, max dose: 18.5mg/m2) until WBC 3,000cells/mm3 reached, stop at this dose, then administer a dose one increment smaller at weekly intervals for maintenance. Usual weekly dosage: 5.5–7.4mg/m2. Do not give the next dose, even if 7 days have elapsed, unless WBC ≥4,000cells/mm3. If oncolytic effect occurs before leukopenia, do not increase the size of subsequent doses. Hepatic impairment: reduce dose by 50% if serum bilirubin >3mg/100mL.

Children:

See literature. IV use only. Testicular germ cell carcinomas: initially 3mg/m2. Adjust dose according to hematologic tolerance.

Contraindications:

Significant granulocytopenia (unless result of disease being treated). Bacterial infections (treat first).

Warnings/Precautions:

For IV use only; fatal if given intrathecally. Hepatic impairment. Avoid in elderly with cachexia or ulcerated skin; or in patients with malignant-cell infiltration of the bone marrow. Pre-existing pulmonary dysfunction. Progressive dyspnea requiring chronic therapy (do not re-administer). Ischemic cardiac disease. Bone marrow suppression; monitor WBC before and during treatment. Avoid contamination of the eyes or injecting into an extremity with poor circulation (thrombosis possible). Avoid extravasation. Pregnancy (Cat.D), nursing mothers: not recommended.

Pharmacologic Class:

Antimicrotubule agent.

Interactions:

May be potentiated by CYP3A inhibitors (eg, erythromycin). Antagonizes phenytoin.

Adverse Reactions:

Leukopenia, alopecia, GI upset, paresthesias, malaise, pain; dyspnea, severe bronchospasm.

How Supplied:

Pwd—10; Soln—1